Showing posts with label a/h9n2. Show all posts
Showing posts with label a/h9n2. Show all posts

Wednesday, November 4, 2026

#Serologic Evidence of Avian #Influenza Virus Exposure in #Livestock, #Egypt, 2024–2026

 


Abstract

Spillover of influenza A(H5N1) virus to cattle in the United States sparked global concern. We investigated whether endemic avian influenza viruses are potentially spilling over into domestic livestock in Egypt. We detected influenza H9N2 antibodies in 2.5% and H5N1 antibodies in 2.9%–4.5% of tested animals. Additional surveillance will elucidate host infection dynamics.


Source: Emerging Infectious Diseases Journal, https://doi.org/10.3201/eid3212.260869

____

Tuesday, November 3, 2026

Avian #Influenza #Report: October 25 - 31 '26 (Wk 44) (HK CHP, November 3, 2026): 2 New Human Infections with #H5N1 virus in #USA & 2 cases with #H9N2 virus in #China

 


{Excerpts}

(...)


Avian influenza A(H5N1)

    ° Washington State:

        § The Washington State Department of Health reported the second and  third human infection with avian influenza A(H5N1) from Yakima County.

        § The second case, who had underlying health conditions, was  hospitalised with severe illness and passed away on November 1, 2026.

        § The third case has not experienced severe illness or been hospitalised.

        § Both cases had exposure to dairy cattle infected with avian influenza  A(H5N1) virus at local dairy farms.

(...)


Avian influenza A(H9N2):

    ° Hubei Province:

        § A two-year-old boy with onset on September 22, 2026.

    ° Jiangxi Province:

        § A 77-year-old woman with onset on September 16, 2026.

(...)


Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk44.pdf

____

Wednesday, October 28, 2026

#Influenza at #human - #animal #interface - #Summary and #risk #assessment, 7 Sept. - 7 Oct. '26 (WHO, Oct. 28 '26): 1 New H5N1 case in #Cambodia, 4 #H9N2 in #China, 1 #H1N1v in #Brazil



• New human cases {2}: 

        ° From 7 September to 7 October 2026, based on reporting date,  detections of influenza A(H5N1) in one human, influenza A(H9N2) in four  humans and influenza A(H1N1) variant (A(H1N1)v) in one human were  officially reported.


• Circulation of influenza viruses with zoonotic potential in animals: 

    ° High pathogenicity avian influenza (HPAI) events in poultry and non- poultry animal species continue to be reported to the World Organisation for  Animal Health (WOAH).{3} The Food and Agriculture Organization of the United  Nations (FAO) also provides a global update on avian influenza viruses with  pandemic potential.{4} Additionally, low pathogenicity avian influenza viruses as  well as swine influenza viruses continue to circulate in animal populations.


• Risk assessment {5}: 

    ° There have been no reports of sustained human-to-human  transmission associated with the above-mentioned human infection events.  Based on information available at the time of this update, the overall public health  risk from currently known influenza A viruses detected at the human-animal interface has not changed and, at present, these viruses are not thought to be capable of sustained human-to-human transmission, although  this could change as they evolve. Whilst human infections with viruses of animal  origin are infrequent, they are not unexpected at the human-animal interface.


• Risk management: 

    ° Candidate vaccine viruses (CVVs) for zoonotic influenza viruses  intended for pandemic preparedness purposes, were reviewed and updated at the  September 2026 WHO consultation on influenza vaccine composition for use in the  Southern Hemisphere 2027 influenza season. A detailed summary of zoonotic  influenza viruses characterized since February 2026 is published and updated CVVs lists are published.


• IHR compliance {6}: 

    ° This includes any influenza A virus that has demonstrated the capacity to  infect a human, and its haemagglutinin (HA) gene (or protein) is not a mutated  form of those, i.e. A(H1) or A(H3), circulating widely in the human population.  Information from these notifications is critical to inform risk assessments for  influenza at the human-animal interface. 


Avian influenza viruses in humans

    ° A(H5N1), Cambodia

        § On 27 September 2026, Cambodia notified WHO of a laboratory- confirmed human infection with an avian influenza A(H5N1) virus in an adult  male, from Oddar Meanchey Province. He developed a runny nose on 24  September, and respiratory swabs collected that day tested positive for influenza A(H5N1) at the National Institute of Public Health on 26 September.  Institut Pasteur du Cambodge, a WHO H5 Reference Laboratory, confirmed the  result on 27 September. The patient was admitted to a referral Hospital for isolation, clinical monitoring and oseltamivir treatment. Genomic sequencing of  the virus from this case could not be done due to a low viral load.

    § The national and provincial Rapid Response Teams, in collaboration  with animal health and local authorities, are conducting epidemiological,  environmental and animal health investigations. The  patient frequently visited a family member’s poultry farm. At the farm, chickens began becoming ill and  dying around 13 September. Poultry specimens collected from remaining birds on 22 September tested positive for avian influenza.

    § Additional specimens were collected for testing from five direct contacts  with the case and three persons with poultry exposure and all were negative for  influenza A(H5N1). All identified contacts are being monitored for symptoms 14 days.

    § This is the sixth case reported in Cambodia in 2026.

    § According to reports received by WOAH, various influenza A(H5)  subtypes continue to be detected in wild and domestic birds in Africa, the  Americas, Asia, Europe and Oceania. Infections in non-human mammals are also reported, including in marine and land mammals.{7} A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{8}


    ° Risk assessment for avian influenza A(H5N1) viruses:

        1. What is the current global public health risk of additional human cases of  infection with avian influenza A(H5N1) viruses?

            § Most human infections so far have been reported in people exposed to A(H5N1) viruses, for example, through contact with infected  poultry or contaminated environments, including live poultry markets, and  occasionally infected mammals and contaminated environments. As long as the  viruses continue to be detected in animals and related environments humans are  exposed to, further human cases associated with such exposures are expected but  remain unusual. 

            § The impact for public health if additional sporadic cases are detected is minimal. 

            § The current overall global public health risk is low.

        2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H5N1) viruses related to the events above?

            § No sustained human-to-human transmission has been identified  associated with the recent reported human infections with avian influenza  A(H5N1) viruses. There has been no reported human-tohuman transmission of  A(H5N1) viruses since 2007, although there may be gaps in investigations. In 2007 and the years prior, small clusters of A(H5N1) virus infections in humans  were reported, including some involving health care workers, where limited  human-to-human transmission could not be excluded; however, sustained human- to-human transmission was not reported. 

            § Current evidence suggests that influenza A(H5N1) viruses  related to these events did not acquire the ability to efficiently transmit  between people.

        3. What is the likelihood of international spread of avian influenza A(H5N1) viruses by travellers?

            § Should infected individuals from affected areas travel internationally,  their infection may be detected in another country during travel or  after arrival. If this were to occur, further community-level spread is  considered  unlikely as current evidence suggests these viruses have  not acquired the ability to transmit easily among humans.  


    ° A(H9N2), China

        § Between 9 and 30 September 2026, China notified WHO of four  laboratory-confirmed human cases of A(H9N2) virus infection.


        [Age - Province - Symptom onset]

        1} < 5-year-old - Henan - 30 August 2026

        2} < 5-year-old - Guangdong - 7 September 2026

        3} Adult - Henan - 17 September 2026

        4)} < 5-year-old - Guizhou - 20 September 2026


        § Three of the cases with mild symptoms were detected in influenza-like  illness surveillance and have recovered. The adult has underlying chronic conditions and was still in hospital at the time of reporting. 

        § All cases had direct or indirect exposure to poultry and/or local live  bird markets. Samples from environments associated with the likely area of  exposure of some of the cases tested positive for A(H9) viruses. 

        § No further cases were detected among contacts of these cases.


    ° Risk assessment for avian influenza A(H9N2):

        1. What is the global public health risk of additional human cases of infection  with avian influenza A(H9N2) viruses?

            § Most human cases follow exposure to the A(H9N2) virus through  contact with infected poultry or contaminated environments. Most human  infections of A(H9N2) to date have resulted in mild clinical illness. Since the virus  is endemic in poultry in multiple countries in Africa and Asia, additional human  cases associated with exposure to infected poultry or contaminated environments  are expected but remain unusual. The impact to public health if additional  sporadic cases are detected is minimal. The overall global public health risk is low.


        2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H9N2) viruses related to these events?

            § At the present time, no sustained human-to-human transmission  has been identified associated with the recently reported human  infections with A(H9N2) viruses. Current evidence suggests that A(H9N2) viruses  from these cases did not acquire the ability of sustained transmission among humans.

        

        3. What is the likelihood of international spread of avian influenza A(H9N2)  virus by travellers? 

            § Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community level spread is considered  unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired  the ability to transmit easily among humans. Swine influenza viruses in humans


    ° Influenza A(H1N1)v, Brazil

        § On 30 September 2026, Brazil notified PAHO/WHO of a laboratory- confirmed human infection with an influenza A(H1N1)v virus in an adult woman, with pre-existing chronic conditions, residing in the state of Santa  Catarina. She developed symptoms of influenza-like illness on 16 July 2026 and  sought medical attention on 20 July. Her husband and three adult children,  who live in the same household, also experienced symptoms of an influenza-like illness; at that time, all were diagnosed, based solely on clinical  examination, with a viral infection and received treatment. The woman,  however, did not recover. On 27 July, the patient was hospitalized due to worsening respiratory symptoms. She received treatment, including the  antiviral oseltamivir, and required intensive care, including ventilatory support. Despite intensive care, the patient passed away on 28 August.

        § A nasopharyngeal sample, collected on 29 July, tested positive for  influenza A on 30 July and was subsequently subtyped as influenza A(H1N1) on 31  July. The sample was sent to the reference laboratory for respiratory viruses  at the Oswaldo Cruz Institute (IOC/Fiocruz) in Rio de Janeiro for further  characterization. On 4 September, genomic analysis identified an influenza  A(H1N1)v virus. 

        § According to information gathered during an epidemiological investigation conducted by municipal and state teams between 5 and 9  September, the patient had no history of travel or direct contact with  swine. However, a possible indirect exposure to swine was identified through  a neighbour who raises these animals for personal consumption.

        § Since 2015, twelve cases of human infection with swine-origin virus  variants, including this one, have been detected within Brazil’s respiratory virus  surveillance workflow. 


    ° Risk Assessment:

        1. What is the public health risk of additional human cases of infection with  swine influenza viruses?

            § Swine influenza viruses circulate in swine populations in many  regions of the world. Depending on geographic location, the genetic characteristics  of these viruses differ. Most human cases are exposed to swine  influenza viruses through contact with infected animals or contaminated environments. Human infection tends to result in mild clinical illness  in most cases. Since these viruses continue to be detected in swine  populations, further human cases are expected but remain unusual. The impact  for public health if additional cases are detected is minimal. The overall risk of additional human cases is low.


        2. What is the likelihood of sustained human-to-human transmission of  swine influenza viruses?  

            § No sustained human-to-human transmission was identified  associated with the event described above. Current evidence suggests that  contemporary swine influenza viruses have not acquired the ability of sustained  transmission among humans, therefore sustained human-to-human transmission  is thus currently considered unlikely.


        3. What is the likelihood of international spread of swine influenza viruses by  travelers?  

            § Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel  or after arrival. If this were to occur, further community level spread is considered  unlikely as current evidence suggest that these viruses have not acquired the ability to transmit easily among humans.


    For more information on zoonotic influenza viruses, see the report from  the WHO Consultation on the Composition of Influenza Virus Vaccines for Use in  the Southern Hemisphere Influenza Season that was held on 21-24 September 2026 at this link. 


Overall risk management recommendations:

    ° Surveillance and investigations

        • Due to the constantly evolving nature of influenza viruses, WHO  continues to stress the importance of global strategic surveillance in animals and  humans to detect virologic, epidemiologic and clinical changes associated with  circulating influenza viruses that may affect human (or animal) health. Continued  vigilance is needed within affected and neighbouring areas to detect infections in  animals and humans. Close collaboration with the animal health and environment  sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published  guidance on surveillance for human infections with avian influenza A(H5) viruses.

        • Epidemiologic and virologic surveillance and the follow-up of  suspected human cases should continue systematically. Guidance on investigation  of non-seasonal influenza and other emerging acute respiratory diseases has been  published on the WHO website.

        • Countries should increase avian influenza surveillance in domestic  and wild birds, enhance surveillance for early detection in cattle  populations in countries where HPAI is known to be circulating, include HPAI as a  differential diagnosis in non-avian species, including cattle and other livestock  populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in  all animal species, including unusual hosts, to WOAH and other international  organizations, share genetic sequences of avian influenza viruses in publicly  available databases, implement preventive and early response measures to break  the HPAI transmission cycle among animals through movement restrictions of  infected livestock holdings and strict biosecurity measures in all holdings, employ  good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals. {7} More guidance can be  found from WOAH and FAO.

        • When there has been human exposure to a known outbreak of an  influenza A virus in domestic poultry, wild birds or other animals – or when there  has been an identified human case of infection with such a virus – enhanced  surveillance in potentially exposed human populations becomes necessary.  Enhanced surveillance should consider the health care seeking behaviour of the  population, and could include a range of active and passive health care and/or  communitybased approaches, including: enhanced surveillance in local influenza- like illness (ILI)/SARI systems, active screening in hospitals and of groups that  may be at higher occupational risk of exposure, and inclusion of other sources  such as traditional healers, private practitioners and private diagnostic laboratories.

        • Vigilance for the emergence of novel influenza viruses with  pandemic potential must be maintained at all times, including during a non- influenza emergency. To maximize the value of influenza surveillance platform for  other respiratory threats, WHO has updated and published practical guidance for integrated surveillance.

    

    ° Notifying WHO

        • All human infections caused by a new subtype of influenza virus are  notifiable under the International Health Regulations (IHR, 2005).{8,9} State  Parties to the IHR (2005) are required to  immediately notify WHO of  any laboratory-confirmed {10}  case of a recent human infection caused by an  influenza A virus with the potential to cause a pandemic {11}. Evidence of  illness is not required for this report. Evidence of illness is not required for this report.

        • WHO published the case definition for human infections with avian  influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions.


    ° Virus sharing and risk assessment

        • It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza  reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP)  Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis {12} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk  of pandemic influenza and to develop candidate vaccine viruses.

        • The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides  an in-depth assessment of risk associated with some zoonotic influenza viruses –  notably the likelihood of the virus gaining human-to-human transmissibility, and  the impact should the virus gain such transmissibility. TIPRA maps relative risk  amongst viruses assessed using multiple risk elements. The results of TIPRA  complement those of the risk assessment provided here, and those of prior TIPRA  risk assessments are published at http://www.who.int/teams/global-influenza-programme/avianinfluenza/tool-for-influenza-pandemic-risk-assessment-(tipra).


    ° Risk reduction

        • Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should  avoid contact with animals that are sick or dead from unknown causes, including  wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.

        • Eggs, poultry meat and other poultry food products should be  properly cooked and properly handled during food preparation. Due to the  potential health risks to consumers, raw milk should be avoided. WHO advises  consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk  until it boils makes it safer for consumption.

        • WHO has published practical interim guidance to reduce the risk of  infection in people exposed to avian influenza viruses.


    ° Trade and travellers

        • WHO advises that travellers to countries with known outbreaks of  animal influenza should avoid farms, contact with animals in live animal markets,  entering areas where animals may be slaughtered, or contact with any surfaces  that appear to be contaminated with animal excreta. Travelers should also wash  their hands often with soap and water. All individuals should follow good food  safety and hygiene practices.

        • WHO does not advise special traveller screening at points of entry or  restrictions with regards to the current situation of influenza viruses at the  human-animal interface. For recommendations on safe trade in animals and  related products from countries affected by these influenza viruses, refer to WOAH  guidance. 


Links:

    ° WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza

    ° WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic)

    ° Global framework to accelerate action on avian  influenza https://iris.who.int/handle/10665/387613

    ° WHO Protocol to investigate non-seasonal influenza and other emerging acute  respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2

    ° WHO Public health resource pack for countries experiencing outbreaks of  influenza in animals: https://www.who.int/publications/i/item/9789240076884

    ° Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1)  Reported to WHO https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus

    ° Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)-virus

    ° World Organisation of Animal Health (WOAH) web page: Avian Influenza https://www.woah.org/en/home/

    ° Food and Agriculture Organization of the United Nations (FAO) webpage:   Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/

    ° WOAH/FAO Network of Expertise on Animal Influenza (OFFLU) http://www.offlu.org/

____

{1} This summary and assessment covers information confirmed during this  period and may include information received outside of this period.

{2} For epidemiological and virological features of human infections with animal  influenza viruses not reported in this assessment, see the reports on human cases  of influenza at the human-animal interface published in the Weekly  Epidemiological Record here.

{3} Avian influenza. Global situation. World Organisation for Animal Health  (WOAH) (https://www.woah.org/en/disease/avian-influenza/#ui-id-2).

{4} Global Avian Influenza Viruses with Zoonotic Potential situation update. Food  and Agriculture Organization of the United Nations (FAO)  (https://www.fao.org/animal-health/situation-updates/global-aiv-with-zoonoticpotential).

{5} Rapid risk assessment of acute public health events. World Health Organization; 2012 (https://iris.who.int/handle/10665/70810).

{6} Case definitions for the four diseases requiring notification in all  circumstances under the International Health Regulations (2005). World Health  Organization; 2009 (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{7} World Organisation for Animal Health. Statement on High Pathogenicity Avian  Influenza in Cattle, 6 December 2024 (https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/).

{8} World Health Organization. International Health Regulations (2005), as  amended through resolutions WHA67.13 (2014), WHA75.12 (2022), and  WHA77.17 (2024) (https://apps.who.int/gb/bd/pdf_files/IHR_2014-2022-2024-en.pdf).

{9} World Health Organization. Case definitions for the four diseases requiring  notification in all circumstances under the International Health Regulations (2005)  (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{10} World Health Organization. Manual for the laboratory diagnosis and  virological surveillance of influenza (2011)  (https://apps.who.int/iris/handle/10665/44518).

{11} World Health Organization. Pandemic influenza preparedness framework for  the sharing of influenza viruses and access to vaccines and other benefits, 2nd  edition (https://iris.who.int/handle/10665/341850).

{12} World Health Organization. Operational guidance on sharing influenza  viruses with human pandemic potential (IVPP) under the Pandemic Influenza  Preparedness (PIP) Framework (2017) (https://apps.who.int/iris/handle/10665/259402)


Source: 


Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--7-october-2026

____

Tuesday, October 20, 2026

Avian #Influenza #Report - October 11 - 17 '26 (Wk 42) (HK CHP, Oct. 20 '26): 1 New Human Case of #H5N1 Virus in the #US; 2 New #H9N2 Virus Cases in #China

 


{Excerpts}

(...)


Avian influenza A(H5N1)

    ° {USA} Washington:

        § The patient is currently isolating at home and has not experienced severe illness or required hospitalisation.

        § The case had exposure to dairy cattle infected with avian influenza A(H5N1) virus at a local dairy farm.

        § The Washington state recorded their first detection of avian influenza  A(H5N1) in two dairy farms on October 8, 2026.


Avian influenza A(H9N2)

    °{China} Guizhou Province:

        § A four-year-old boy with onset on September 20, 2026.

    ° Henan Province:

        § A 68-year-old man with onset on September 17, 2026.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk42.pdf

____

#Bat-borne #influenza A #H9N2 virus shows species-specific #replication and #transmission

 


Abstract

Bat-borne H9N2 IAV (bat H9N2), initially detected in bat feces in Egypt in 2017, has recently attracted attention because of its unexpected pre-pandemic properties, including airborne transmission between ferrets and efficient replication in human lung explant cultures. However, its host range and potential reservoir hosts remain poorly defined, particularly with respect to additional bat hosts and mammalian or avian mixing-vessel species. Here, we compare the susceptibility of two pteropodid bat species, Rousettus aegyptiacus and Eidolon helvum, and additionally assessed pigs and quails following intranasal inoculation with bat H9N2. Juvenile R. aegyptiacus showed only low-level viral replication and shedding, largely restricted to the upper respiratory tract, and did not show transmission to contact bats. In contrast, both juvenile and adult E. helvum, despite showing no clinical signs, showed high-level viral replication and shedding in the upper respiratory tract, with efficient and early transmission to contact bats. Viral RNA was most abundant in the respiratory turbinates, the nasopharyngeal meatus and the tracheal epithelium, where it was associated with moderate to severe necrotizing rhinitis and tracheitis. The lower respiratory tract was less involved, with viral RNA confined to scattered bronchioles and associated with focal necrotizing bronchiolitis. Other organs, including the gastrointestinal tract, lacked histologic lesions and viral RNA labeling. In pigs and quails, intranasal inoculation did not result in detectable replication, transmission, or seroconversion. Our findings demonstrate marked differences in the susceptibility to bat H9N2 between the two fruit bat species tested and identify E. helvum as a highly susceptible host capable of rapid and efficient transmission. Conversely, pigs and quails were not susceptible, suggesting that additional viral adaptations may be required to allow for a productive infection in these species.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://doi.org/10.64898/2026.10.15.759517

____

Wednesday, September 30, 2026

N70S/Y155H Combined #Mutation of #Neuraminidase of Avian #Influenza #H9N2 Virus confers #oseltamivir and #zanamivir #resistance and pathogenicity to Mice

 


Highlights

    • H9N2 viruses recently circulating in China harbors novel N70S/Y155H dual mutations in N2;

    • H9N2 viruses with N70S/Y155H mutations exhibit high pathogenicity to BALB/c mice.

    • N70S/Y155H linked mutations in N2 confer resistance to oseltamivir and zanamivir, rather than peramivir.

    • Neuraminidase inhibitors exhibited limited efficacy on H9N2 virus with novel N70S /Y155H dual mutations.


Abstract

Recently, H9N2 avian influenza virus (AIV) poses a significant threat to both the poultry industry and public health. Therefore, investigating the impact of its neuraminidase mutations on susceptibility to neuraminidase inhibitors (NAIs) is of great importance for clinically preventing potential cross-species transmission of H9N2. In this study, our results revealed that NAI resistance-related mutations of most H9N2 viruses isolated from China during 1998 to 2024 mainly occurred at positions N70S, E119A/D/G/V, Q133K, Q136A, D151E, Y155H, I222V, R224K, E276D, R292K, N294S, and R371K. Among them, the combined N70S and Y155H mutations are common characteristics of H9N2 viruses circulating in recent years. In vivo experiments demonstrated that these H9N2 viruses harboring the combined N70S and Y155H mutations exhibit high pathogenicity to BALB/c mice without prior adaption. In vitro neuraminidase inhibition assays confirmed that these H9N2 viruses bearing the N70S/Y155H mutations exhibited greater reduced inhibition than their counterparts bearing the N70S or Y155H single mutation to oseltamivir and zanamivir, but remained highly sensitive to peramivir. Notably, the in vivo protective effect of NAIs against H9N2 virus with combined N70S and Y155H mutations is limited, possibly due to the restricted ability of these drugs to ameliorate the excessive inflammatory responses. Therefore, there is an urgency to strengthen research on epidemiological surveillance and prevention strategies for avian influenza H9N2 harboring these mutations.

Source: 


Link: https://doi.org/10.1016/j.antiviral.2026.106540

____

Tuesday, September 29, 2026

Avian #Influenza #Report: September 20 - 26 '26 (Wk 39) (HK CHP, Sept. 29 '26): 1 New #H5N1 Human Case in #Cambodia, 2 New #H9N2 Cases in #China

 


{Excerpts}

(...)

    ° Avian influenza A(H5N1)

        § Oddar Meanchey Province:

            - The case involved a 49-year-old man.

            - He has been isolated in the hospital and is receiving intensive medical  care. 

            - The patient worked at a farm and had direct contact with sick and dead chickens which tested positive for avian influenza A(H5N1) virus.

(...)

    ° Avian influenza A(H9N2):

        § Guangdong Province:

            - A one-year-old girl with onset on September 7, 2026.

        § Henan Province:

            - A one-year-old girl with onset on August 30, 2026.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk39.pdf

____

Tuesday, September 22, 2026

Avian #influenza #overview June–August 2026 (ECDC/EFSA, September 22 '26, Summary)

 


{Summary}


Abstract

    Between 5 June and 28 August 2026, 110 highly pathogenic avian  influenza (HPAI) A(H5N1) virus detections were reported in domestic (7)  and wild (103) birds in 12 countries in Europe. The number of detections  remained at a seasonal low throughout the summer, continuing the decline  observed since spring. In contrast to previous years, fewer colony-breeding  seabirds were affected, and the geographical range of detections was more  limited. Further sporadic detections of HPAI A(H5) virus were reported in wild  terrestrial carnivores and pinnipeds. Outside Europe, the epidemic continued  in the Americas, where also the HPAI A(H7N3) subtype was detected in Mexico.  Following its first introduction to mainland Australia, HPAI A(H5N1) virus spread within local wild bird populations and spilled over to terrestrial  carnivores and marine mammals. In the US, the number of dairy  cattle farms reportedly affected by HPAI A(H5N1) increased, while detections in  captive American minks were reported for the first time. Between 5 June and  31 August 2026, 15 cases of avian influenza virus infection were publicly  reported in humans (no fatal cases) in three countries and territories:  Bangladesh (one A(H5N1) case), Cambodia (one A(H5N1) case) and China (13 A(H9N2) cases). All human cases reported exposure to poultry or a poultry  environment prior to detection or onset of illness. Human infections with avian  influenza viruses remain rare and no sustained human-to-human transmission has  been documented. The risk posed by avian influenza A(H5N1) clade  2.3.4.4b viruses currently circulating in Europe remains low for the general  public in the European Union/European Economic Area (EU/EEA) and low-to- moderate for those occupationally or otherwise exposed to infected animals or  contaminated environments.


©2026 European Food Safety Authority, European Centre for Disease Prevention  and Control, European Union Reference Laboratory for Avian Influenza. EFSA  Journal published by WileyVCH GmbH on behalf of European Food Safety Authority

(...)

Source: 


Link: https://doi.org/10.2903/j.efsa.2026

____

Tuesday, September 15, 2026

Avian #Influenza #Report: September 6 - 12 '26 (Wk 37) (HK CHP, Sept. 15 '26): 1 new confirmed #human case of #infection with #H9N2 virus in #China

 


{Excerpt}

(...)

Avian influenza A(H9N2):

    ° Guangxi Zhuang Autonomous Region:

        § A two-year-old boy with onset on August 23, 2026.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk37.pdf

____

Tuesday, September 8, 2026

Avian Influenza Report: August 30 – September 5 '26 (Wk 36) (CHP, HK SAR, September 8, '26): 1 New Human Case of Infection with #H9N2 virus in #China

 


{Excerpt}

(...)

Avian influenza A(H9N2):

    ° Beijing:

        § A six-year-old girl with onset on August 15, 2026.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk36.pdf

____

Tuesday, September 1, 2026

Avian #Influenza #Report: August 23 - 29 '26 (Wk 35) (CHP, HK SAR September 1, 2026): 1 New #Human Infection with #H9N2 virus in Anhui, 20 cases so far this year


 

{Excerpt}

(...)

Avian influenza A(H9N2):

    ° Anhui Province {China}:

        § A three-year-old boy with onset on August 3, 2026.

(...)

Source: Centre for Health Protection, Hong Kong PRC SAR, https://www.chp.gov.hk/en/index.html

Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk35.pdf

____

Wednesday, August 19, 2026

#Influenza at #human - #animal #interface - Summary & #risk #assessment, from 8 July to 7 August '26 (WHO, edited): 2 new #H5N1 cases in #Bangladesh & #Cambodia, 8 new #H9N2 cases in #China



Influenza at the human - animal #interface - Summary and risk assessment, from 8 July to 7 August 2026 {1}


    • New human cases {2}: 

        * From 8 July to 7 August 2026, based on reporting date, detections of influenza A(H5N1) in one human and influenza A(H9N2) in eight humans  were officially reported. 

    • Circulation of influenza viruses with zoonotic potential in animals: 

        ° High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for  Animal Health (WOAH).{3} The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with  pandemic potential.{4} Additionally, low pathogenicity avian influenza viruses as  well as swine influenza viruses continue to circulate in animal populations.

    • Risk assessment {5}: 

        * There have been no reports of sustained human-to-human transmission associated with the above-mentioned human infection events.  Based on information available at the time of this risk assessment update, the  overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and, at present, these  viruses are not thought to be capable of sustained human-to-human transmission, although this could change as they evolve. Although human  infections with viruses of animal origin are infrequent, they are not unexpected at  the human-animal interface.

    • IHR compliance {6}: 

        * This includes any influenza A virus that has demonstrated the capacity  to infect a human and its haemagglutinin (HA) gene (or protein) is not a  mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human  population. Information from these notifications is critical to inform risk  assessments for influenza at the human-animal interface.


Avian influenza viruses in humans

    ° A(H5N1), Bangladesh

        § The case included in the risk assessment of 7 July 2026 in a child from Sylhet Division was confirmed as an A(H5N1) virus infection.


    ° A(H5N1), Cambodia

        § On 10 July 2026, Cambodia notified WHO of one laboratory-confirmed human case of avian influenza A(H5N1) infection detected in a child in Phnom Penh who developed a fever on 30 June 2026. After several days of  treatment at a private clinic without improvement, she was admitted to hospital  on 7 July with bronchopneumonia. Oropharyngeal and nasopharyngeal swabs  collected on 8 July were tested at the Institut Pasteur du Cambodge and reverse  transcription polymerase chain reaction (RT-PCR) testing confirmed influenza  A(H5N1) on 10 July, with positive results confirmed through repeat testing. The  specimen was subsequently tested at the National Institute of Public Health, which  also confirmed influenza A(H5N1). The patient was in stable clinical condition, treated with oseltamivir and subsequently recovered.

        § Sequence analysis identified the virus as a clade 2.3.2.1e virus,  closely related to viruses that have been circulating in poultry and causing  sporadic human infections in Cambodia since 2023.

        § Following laboratory confirmation, the national and Phnom Penh  Municipal Rapid Response Teams, in collaboration with the Ministry of Agriculture,  Forestry and Fisheries and local authorities, initiated epidemiological,  environmental and animal health investigations, including active case finding and assessments of potential poultry and environmental exposures. 

        § Neighbouring households kept fighting cocks and free-range chickens  and the patient visited one of these households prior to symptom onset.  The child also had exposure to areas where chicken droppings were found. 

        § At the time of reporting, three animal samples collected from poultry  in neighbouring households for laboratory testing tested negative for influenza  A(H5N1). 

        § Contacts of the case tested negative for influenza A(H5N1) and two  tested positive for SARS-CoV-2.

        § Since 2023, Cambodia has reported 39 laboratory-confirmed human cases, including 16 deaths.


Risk assessment for avian influenza A(H5N1) viruses:

    1. What is the current global public health risk of additional human cases of  infection with avian influenza A(H5N1) viruses?

        ° Most human infections so far have been reported in people exposed to  A(H5N1) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally  infected mammals and contaminated environments. As long as the viruses  continue to be detected in animals and related environments humans are exposed  to, further human cases associated with such exposures are expected  but remain unusual. The impact for public health if additional sporadic cases are detected is minimal. 

        ° The current overall global public health risk is low.


    2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H5N1) viruses related to the events above?

        ° No sustained human-to-human transmission has been identified  associated with the recent reported human infections with avian  influenza A(H5N1) viruses. There has been no reported human-to-human  transmission of A(H5N1) viruses since 2007, although there may be gaps in  investigations. 

        ° In 2007 and the years prior, small clusters of A(H5) virus infections in  humans were reported, including some involving health care workers, where  limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported. 

        ° Current evidence suggests that influenza A(H5N1) viruses related to  these events did not acquire the ability to efficiently transmit between people.


    3. What is the likelihood of international spread of avian influenza A(H5N1) viruses  by travellers?

        ° Should infected individuals from affected areas travel internationally,  their infection may be detected in another country during travel or after arrival. If  this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


    ° A(H9N2), China

        § Between 7 July and 5 August 2026, China notified WHO of eight laboratory-confirmed human cases of A(H9N2) virus infection. 


{Click on Image to Enlarge}

___

        § All cases had direct or indirect exposure to poultry and/or local live  bird markets. Samples from environments associated with the likely area of  exposure of the cases tested positive for A(H9) viruses. 
        
        § No further cases were detected among contacts of these cases.


Risk assessment for avian influenza A(H9N2):

    1. What is the global public health risk of additional human cases of infection with  avian influenza A(H9N2) viruses?

        ° Most human cases follow exposure to the A(H9N2) virus through  contact with infected poultry or contaminated environments. Most human  infections of A(H9N2) to date have resulted in mild clinical illness. Since the  virus is endemic in poultry in multiple countries in Africa and Asia, additional human cases associated with exposure to infected poultry or  contaminated environments are expected but remain unusual. 
        
        ° The impact to public health if additional sporadic cases are detected is 
minimal. 

        ° The overall global public health risk is low.


    2. What is the likelihood of sustained human-to-human transmission of avian  influenza A(H9N2) viruses related to these events?

        ° At the present time, no sustained human-to-human transmission has been identified associated with the recently reported human infections with  A(H9N2) viruses. Current evidence suggests that A(H9N2) viruses from these  cases did not acquire the ability of sustained transmission among humans.


    3. What is the likelihood of international spread of avian influenza A(H9N2)  virus by travellers?

        ° Should infected individuals from affected areas travel internationally,  their infection may be detected in another country during travel or after arrival. If  this were to occur, further community level spread is considered unlikely as  current evidence suggests the A(H9N2) virus subtype has not acquired the ability  to transmit easily among humans.


Overall risk management recommendations:

Surveillance and investigations

    • Due to the constantly evolving nature of influenza viruses, WHO  continues to stress the importance of global strategic surveillance in animals and  humans to detect virologic, epidemiologic and clinical changes associated with  circulating influenza viruses that may affect human (or animal) health. Continued  vigilance is needed within affected and neighbouring areas to detect infections in  animals and humans. Close collaboration with the animal health and environment  sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published  guidance on surveillance for human infections with avian influenza A(H5) viruses.

    • As the extent of influenza virus circulation in animals is not clear,  epidemiologic and virologic surveillance and the follow-up of suspected human  cases should continue systematically. Guidance on investigation of non-seasonal  influenza and other emerging acute respiratory diseases has been published on the WHO website.

    • Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in  countries where HPAI is known to be circulating, include HPAI as a differential  diagnosis in non-avian species, including cattle and other livestock populations,  with high risk of exposure to HPAI viruses; monitor and investigate cases in non- avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations,  share genetic sequences of avian influenza viruses in publicly available databases,  implement preventive and early response measures to break the HPAI  transmission cycle among animals through movement restrictions of  infected livestock holdings and strict biosecurity measures in all holdings, employ  good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{7} More guidance can be  found from WOAH and FAO.

    • When there has been human exposure to a known outbreak of an  influenza A virus in domestic poultry, wild birds or other animals – or when there  has been an identified human case of infection with such a virus – enhanced  surveillance in potentially exposed human populations becomes necessary.  Enhanced surveillance should consider the health care seeking behaviour of the  population, and could include a range of active and passive health care and/or  communitybased approaches, including: enhanced surveillance in local influenza- like illness (ILI)/SARI systems, active screening in hospitals and of groups that  may be at higher occupational risk of exposure, and inclusion of other sources  such as traditional healers, private practitioners and private diagnostic  laboratories.

    • Vigilance for the emergence of novel influenza viruses with pandemic  potential should be maintained at all times including during a non-influenza  emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance.


Notifying WHO

    • All human infections caused by a new subtype of influenza virus are  notifiable under the International Health Regulations (IHR, 2005).{8,9} State  Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed {10} case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic {11}. Evidence of illness  is not required for this report. Evidence of illness is not required for this report.

    • WHO published the case definition for human infections with avian  influenza A(H5) virus requiring notification under IHR (2005):  https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions.


Virus sharing and risk assessment

    • It is critical that these influenza viruses from animals or from humans  are fully characterized in appropriate animal or human health influenza reference  laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework,  Member States are expected to share influenza viruses with pandemic potential on  a timely basis {12} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of  pandemic influenza and to develop candidate vaccine viruses.

    • The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses –  notably the likelihood of the virus gaining human-to-human transmissibility, and  the impact should the virus gain such transmissibility. TIPRA maps relative risk  amongst viruses assessed using multiple risk elements. The results of TIPRA  complement those of the risk assessment provided here, and those of prior TIPRA  risk assessments are published at http://www.who.int/teams/global-influenza-programme/avianinfluenza/tool-for-influenza-pandemic-risk-assessment-(tipra).


Risk reduction

    • Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should  avoid contact with animals that are sick or dead from unknown causes, including  wild animals, and should report dead birds and mammals or request their removal  by contacting local wildlife or veterinary authorities.

    • Eggs, poultry meat and other poultry food products should be properly  cooked and properly handled during food preparation. Due to the potential health  risks to consumers, raw milk should be avoided. WHO advises consuming  pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption.

    • WHO has published practical interim guidance to reduce the risk of  infection in people exposed to avian influenza viruses.


Trade and travellers

    • WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets,  entering areas where animals may be slaughtered, or contact with any surfaces  that appear to be contaminated with animal excreta. Travelers should also wash  their hands often with soap and water. All individuals should follow good food safety and hygiene practices.

    • WHO does not advise special traveller screening at points of entry or  restrictions with regards to the current situation of influenza viruses at the  human-animal interface. For recommendations on safe trade in animals and  related products from countries affected by these influenza viruses, refer to WOAH guidance.


Links:

    ° WHO Human-Animal Interface web page

    ° WHO Influenza (Avian and other zoonotic) fact sheet

    ° WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases

    ° WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:

    ° Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO

    ° Avian Influenza A(H7N9) Information

    ° World Organisation of Animal Health (WOAH) web page: Avian Influenza

    ° Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza

    ° WOAH/FAO Network of Expertise on Animal Influenza (OFFLU)

____

{1} This summary and assessment covers information confirmed during this  period and may include information received outside of this period.

{2} For epidemiological and virological features of human infections with animal  influenza viruses not reported in this assessment, see the reports on human cases  of influenza at the human-animal interface published in the Weekly Epidemiological Record here.

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global  situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2.

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian  Influenza Viruses with Zoonotic Potential situation update. Available at:  https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential.

{5} World Health Organization (2012). Rapid risk assessment of acute public  health events. World Health Organization. Available at:  https://iris.who.int/handle/10665/70810.

{6} World Health Organization. Case definitions for the four diseases requiring  notification in all circumstances under the International Health Regulations  (2005). Available at: https://www.who.int/publications/m/item/case-definitions-for-the-four-diseases-requiring-notification-towho-in-all-circumstances-under-the-ihr-(2005).

{7} World Organisation for Animal Health. Statement on High Pathogenicity Avian  Influenza in Cattle, 6 December 2024 (https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/).

{8} World Health Organization. International Health Regulations (2005), as  amended through resolutions WHA67.13 (2014), WHA75.12 (2022), and  WHA77.17 (2024) (https://apps.who.int/gb/bd/pdf_files/IHR_2014-2022-2024-en.pdf).

{9} World Health Organization. Case definitions for the four diseases requiring  notification in all circumstances under the International Health Regulations (2005)  (https://www.who.int/publications/m/item/casedefinitions-for-the-four-diseases-requiring-notification-to-who-in-all-circumstances-under-the-ihr-(2005)).

{10} World Health Organization. Manual for the laboratory diagnosis and  virological surveillance of influenza (2011)  (https://apps.who.int/iris/handle/10665/44518).

{11} World Health Organization. Pandemic influenza preparedness framework for  the sharing of influenza viruses and access to vaccines and other benefits, 2nd  edition (https://iris.who.int/handle/10665/341850).

{12} World Health Organization. Operational guidance on sharing influenza  viruses with human pandemic potential (IVPP) under the Pandemic Influenza  Preparedness (PIP) Framework (2017) (https://apps.who.int/iris/handle/10665/259402).


Source: 


Link: https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--7-august-2026

_____

My New Space

Most Popular Posts